Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.

With HAVEL LABS, a unique campus is being developed in Berlin-Spandau. ­Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) ­guidelines, can be ­effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in ­accordance with German Genetic Engineering Safety Regulations.

Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.

The “16th European Biotechnology Science & Industry Guide 2026” – the handbook will present the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe. Besides the printed version the guide will also be available as a digital version.

Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.

The Enlarged Board of Appeal (EBoA) of the European Patent Office will decide upon a question of high relevance for patents in the field biotechnology. The question to be decided concerns the interpretation of what has been “made available to the public”.

The city is investing in the future by establishing a modern campus and strengthening Mainz as a hub for life sciences. Space with convenient transport connections close to the city centre is available to found or relocate start-ups, companies and research facilities.

Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.

To address the demands of a growing population and enhance food and nutrition security, a transition from traditional chemical-derived production is essential. Biomanufacturing, known for its efficient use of natural resources, offers an ideal solution. Acies Bio recently added fermentation capacity and more versatile equipment for downstream processing and formulation.

Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.